

## REMARKS

Claims 18, 30 and 32 are currently amended. Claims 27, 28 and 36-40 are canceled. No new matter is added. Reconsideration is requested.

### **I. The Rejection of Claims 36-39 under 35 U.S.C. 112 (Written Description)**

Claims 36-39 are cancelled. Accordingly, any rejection relating to these claims is moot.

### **II. The Rejection of Claims 18-24, 26-27, 29-40 under 35 U.S.C. 103(a)**

Claims 18-24, 26-27, 29-40 stand rejected as obvious in light of U.S. Patent No. 4,009,076 (hereinafter referred to simply as "Green").

Independent claims 18 and 32 are currently amended. Applicant submit that the claims, as amended, overcome this rejection under 35 U.S.C. § 103(a). Applicants respectfully request reconsideration and withdrawal of the rejection.

### **III. The Rejection of Claim 28 under 35 U.S.C. 103(a)**

Claim 28 is canceled. Accordingly, the rejection is moot.

### **IV. The Rejection of Claims 18-24, 26, 29-39 under 35 U.S.C. 103(a).**

Claims 18-24, 26, 29-39 stand rejected as obvious in light of U.S. Patent No. 5,858,952 (hereinafter referred to simply as "Izawa") in view of U.S. Patent No. 6,242,407 (hereinafter referred to simply as "Bertacchi").

Independent claims 18 and 32 are currently amended. Applicant submit that the claims, as amended, overcome this rejection under 35 U.S.C. § 103(a). Applicants respectfully request reconsideration and withdrawal of the rejection.

### **V. The Rejection of Claims 27-28 and 40 under 35 U.S.C. 103(a)**

Claims 27-28 and 40 are cancelled. Accordingly, the rejection is moot.

## **VI. Conclusion**

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application. Should any additional fees be due, the USPTO is authorized to charge the deposit account of Novozymes North America, Inc., *i.e.*, deposit account No. 50-1701.

Respectfully submitted,

Date: May 10, 2010

/Michael W. Krenicky Reg#45411/

Michael W. Krenicky, Reg. No. 45,411  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212)840-0097